Q1 EPS Estimates for Gossamer Bio Decreased by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Gossamer Bio in a report released on Tuesday, March 18th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.16) per share for the quarter, down from their previous estimate of ($0.15). HC Wainwright currently has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio's Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.56) EPS and FY2027 earnings at ($0.04) EPS.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). The business had revenue of $9.38 million during the quarter, compared to analyst estimates of $7.02 million.

Separately, Wedbush reissued an "outperform" rating and issued a $4.00 price target on shares of Gossamer Bio in a report on Friday, March 14th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $9.20.

Remove Ads

Gossamer Bio Stock Performance

GOSS stock traded down $0.11 during midday trading on Thursday, reaching $1.28. The company had a trading volume of 1,581,613 shares, compared to its average volume of 1,566,336. The firm has a market capitalization of $290.84 million, a PE ratio of -4.00 and a beta of 1.86. The stock has a 50 day moving average price of $1.16 and a 200 day moving average price of $0.98. Gossamer Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.55. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds have recently made changes to their positions in GOSS. GSA Capital Partners LLP acquired a new position in Gossamer Bio during the 3rd quarter worth $67,000. The Manufacturers Life Insurance Company raised its stake in shares of Gossamer Bio by 24.2% during the third quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company's stock valued at $380,000 after purchasing an additional 74,920 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Gossamer Bio by 30.7% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company's stock worth $1,862,000 after purchasing an additional 442,895 shares during the period. Charles Schwab Investment Management Inc. grew its position in Gossamer Bio by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock valued at $1,123,000 after buying an additional 13,902 shares in the last quarter. Finally, Monaco Asset Management SAM increased its stake in Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock valued at $4,859,000 after buying an additional 1,520,721 shares during the period. Institutional investors own 81.23% of the company's stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.